Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Progressive Corp (PGR) Price & Performance

Heron Therapeutics IncTrade
Progressive CorpTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Progressive Corp — how do they compare? Heron Therapeutics Inc trades at $0.34 (market cap $61.47M), while Progressive Corp trades at $211.86 (market cap $123.45B). The key difference: Progressive Corp is far larger — about 2008.3× Heron Therapeutics Inc's market cap, and Progressive Corp pays a 6.55% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HRTXPGR
Market Cap
$61.47M$123.45B
Sector
HealthFinancials
52-Week High
$1.49$252.68
52-Week Low
$0.32$190.40
Enterprise Value
$168.21M$131.66B
Dividend Yield
6.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

Progressive Corp

Progressive (PGR) trades at $213.95, down 0.64% on the day, with a bullish technical outlook supported by moving averages. The company shows strong fundamental performance with revenue growing from $49.6B in 2022 to $87.6B in 2025 and net income reaching $11.3B. Recent Q2 2026 earnings beat expectations at $4.85 per share, though the combined ratio widened to 87.1%, indicating potential growth trade-offs. Analyst consensus price target stands at $231.20 with 37% buy ratings.

PGR presents a compelling investment case with reasonable valuation (P/E 10.65) and strong profitability (ROE 34.94%), though investors face risks from competitive pressures and potential margin compression as the company expands its bundled insurance offerings. The stock offers 8% upside to consensus target with balanced risk-reward profile.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Progressive Corp

Progressive underwrites private and commercial auto insurance and specialty lines

Read more on PGR